CHMP Backs Trodelvy+Keytruda in 1L PD-L1+ TNBC

Key Takeaways

• CHMP recommended Trodelvy plus pembrolizumab for 1L metastatic TNBC with PD-L1 CPS ≥10.
• ASCENT-04/KEYNOTE-D19 showed a 35% reduced risk of progression or death vs chemo plus pembrolizumab.
• EMA already lists Trodelvy monotherapy for 1L patients who are not PD-(L)1 candidates.
• European Commission decision is expected later in 2026, per Gilead.

Trodelvy plus Keytruda at a glance

Field	Detail
Products	Trodelvy (sacituzumab govitecan) + Keytruda (pembrolizumab)
Companies	Gilead; Merck (Keytruda)
Regulator action	CHMP positive variation opinion (23 July 2026)
Population	1L unresectable locally advanced/metastatic TNBC; PD-L1 CPS ≥10
Key trial	ASCENT-04 / KEYNOTE-D19 (NCT05382286)
Key efficacy	35% lower risk of progression or death vs chemo+pembrolizumab
Next step	European Commission decision (later 2026)

What did CHMP recommend?

EMA's Trodelvy variation page states that on 23 July 2026 CHMP adopted a positive opinion recommending Trodelvy in combination with pembrolizumab for adults with unresectable locally advanced or metastatic TNBC who have not received prior systemic therapy for metastatic disease and whose tumours express PD-L1 with CPS ≥10. The draft full indications also keep monotherapy uses for PD-(L)1-ineligible first-line patients and for later-line TNBC and HR+/HER2− disease.

Primary source: EMA's Trodelvy variation opinion.

What did ASCENT-04 show?

Gilead said ASCENT-04/KEYNOTE-D19 demonstrated a highly statistically significant and clinically meaningful progression-free survival benefit for Trodelvy plus Keytruda versus standard-of-care chemotherapy plus Keytruda in PD-L1-positive first-line metastatic TNBC, including a 35% reduction in the risk of disease progression or death. The study used a patient-centred crossover design allowing chemotherapy-arm patients to receive Trodelvy after progression.

Registry: ClinicalTrials.gov NCT05382286. Peer-reviewed listing: PubMed ASCENT-04 / KEYNOTE-D19 record.

How does this fit existing Trodelvy EU labels?

Gilead noted the European Commission has already approved Trodelvy monotherapy for unresectable or metastatic TNBC in patients not candidates for PD-1/PD-L1 inhibitor therapy. A second first-line authorisation for the PD-L1-positive combination would, if granted, position Trodelvy across PD-L1 status in the metastatic first-line EU setting.

July plenary context: EMA CHMP highlights 20–23 July 2026.

Why PD-L1-positive metastatic TNBC needs faster options?

Metastatic TNBC progresses quickly and has historically limited targeted choices. Gilead estimates about 40% of metastatic TNBC tumours are PD-L1 positive and argues first-line therapy is often the only line many patients receive. Pairing a Trop-2 ADC with PD-1 blockade aims to improve disease control earlier.

What should oncology teams watch?

• Final CPS assay language and companion-testing logistics
• Neutropenia, diarrhoea and other ADC toxicities when stacked with pembrolizumab
• Sequencing versus Trodelvy monotherapy for PD-(L)1-ineligible patients
• HTA framing of the 35% risk reduction versus chemo-pembrolizumab

Commission timing and national reimbursement will decide when hospitals can switch pathways.

What remains uncertain?

Overall survival maturity, crossover confounding, and real-world PD-L1 testing concordance are still evolving. Cross-trial comparisons with other Trop-2 or ADC combinations remain speculative until shared endpoints and populations align.

Related NovaPharma coverage

• CHMP July 2026: 12 New Medicines Recommended
• EMA Backs Etcamah for ESR1+ Breast Cancer
• ESMO 2026 Preview: Madrid Oncology Catalysts

Frequently Asked Questions

Primary Sources

1. EMA: Trodelvy variation opinion — 23 July 2026
2. ClinicalTrials.gov: ASCENT-04 NCT05382286
3. PubMed: ASCENT-04 / KEYNOTE-D19
4. EMA: CHMP meeting highlights 20–23 July 2026